T-Cell Depleted Double UCB With Post Transplant IL-2 for Refractory Myeloid Leukemia.

Trial Profile

T-Cell Depleted Double UCB With Post Transplant IL-2 for Refractory Myeloid Leukemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs Allopurinol (Primary) ; Busulfan (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Levetiracetam (Primary) ; Cord blood stem cell therapy; Interleukin-2
  • Indications Acute myeloid leukaemia; Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 07 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top